Recent insights into the mechanism of action of glatiramer acetate. Kala M, Miravalle A, Vollmer T J Neuroimmunol. 2011 Jun; 235(1-2):9-17. Epub 2011 Mar 13. PMID: 21402415. Abstract
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V N Engl J Med. 1987 Aug 13; 317(7):408-14. PMID: 3302705. Abstract
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB Neurology. 1995 Jul; 45(7):1268-76. PMID: 7617181. Abstract
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. Comi G, Filippi M, Wolinsky JS Ann Neurol. 2001 Mar; 49(3):290-7. PMID: 11261502. Abstract
ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE(R) MarketWatch, The Wall Street Journal, 11 Oct 2011 Accessed on 4 Jan 2012 from http://www.marketwatch.com/story/significant-reduced-loss-of-brain-volume-in-multiple-sclerosis-patients-treated-with-copaxoner-2011-10-11.
Drugs@FDA (Enter "glatiramer acetate" in search box.) FDA Accessed on 4 Jan 2012 from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, et al. Mult Scler. 2010 Mar; 16(3):342-50. Epub 2010 Jan 27. PMID: 20106943. Abstract
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Johnson KP Ther Clin Risk Manag. 2010; 6:153-72. Epub 2010 Apr 15. PMID: 20421914. Abstract
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B M, REGARD study group Lancet Neurol. 2008 Oct; 7(10):903-14. Epub 2008 Sep 11. PMID: 18789766. Abstract
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H-P, Jeffery D, Kappos L, Boateng F, et al. Lancet Neurol. 2009 Oct; 8(10):889-97. Epub 2009 Sep 02. PMID: 19729344. Abstract
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD Neurology. 2009 Jun 9; 72(23):1976-83. Epub 2009 Mar 11. PMID: 19279320. Abstract
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, et al. Lancet. 2009 Oct 31; 374(9700):1503-11. Epub 2009 Oct 06. PMID: 19815268. Abstract
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study. Lackner P, Part A, Burger C, Dietmann A, Broessner G, Helbok R, Reindl M, Schmutzhard E, Beer R Malar J. 2009; 8:36. Epub 2009 Feb 27. PMID: 19250545. Abstract
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Meininger V, Drory VE, Leigh NP, Ludolph A, Robberecht W, Silani V Amyotroph Lateral Scler. 2009 Oct-Dec; 10(5-6):378-83. PMID: 19922128. Abstract
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, Tomov TL, Yoles E, Kipnis J, Schori H, Reuter A, et al. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4790-5. Epub 2003 Mar 31. PMID: 12668759. Abstract
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A Curr Eye Res. 2008 Nov; 33(11):1011-3. PMID: 19085384. Abstract
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M Proc Natl Acad Sci U S A. 2006 Aug 1; 103(31):11784-9. Epub 2006 Jul 24. PMID: 16864778. Abstract
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, Arnon R J Pharmacol Exp Ther. 2006 Jul; 318(1):68-78. Epub 2006 Apr 19. PMID: 16624971. Abstract
Copolymer 1 inhibits manifestations of graft rejection. Aharoni R, Teitelbaum D, Arnon R, Sela M Transplantation. 2001 Aug 27; 72(4):598-605. PMID: 11544417. Abstract
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. Gorantla S, Liu J, Sneller H, Dou H, Holguin A, Smith L, Ikezu T, Volsky DJ, Poluektova L, Gendelman HE J Immunol. 2007 Oct 1; 179(7):4345-56. PMID: 17878329. Abstract
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, et al. Ann Neurol. 2007 Jan; 61(1):14-24. PMID: 17262850. Abstract
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA J Clin Invest. 2000 Apr; 105(7):967-76. PMID: 10749576. Abstract
Our Products (page shows "Copaxone" as a trade name for glatiramer acetate) Teva Accessed on 4 Jan 2012 from http://www.tevapharm.com/en-US/Products/Pages/default.aspx.
Multiple sclerosis: clinical presentation, diagnosis and treatment. Brod SA, Lindsey JW, Wolinsky JS Am Fam Physician. 1996 Sep 15; 54(4):1301-6, 1309-11. PMID: 8816574. Abstract
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe) ClinicalTrials.gov, 4 Apr 2011 Accessed on 16 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00666224.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators Mult Scler. 2009 Oct; 15(10):1183-94. Epub 2009 Sep 23. PMID: 19776092. Abstract
Full Prescribing Information, Copaxone (glatiramer acetate) FDA, Feb 2009 Accessed on 4 Jan 2012 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf.
Glatiramer acetate in the treatment of multiple sclerosis Tselis A, Khan O, Lisak RP, Apr 2007 Accessed on 21 Mar 2012 from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654627/. Neuropsychiatr Dis Treat. 2007 April; 3(2): 259–267.
Phase IV, Rater-blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-dose Gadolinium ClinicalTrials.gov, 6 May 2010 Accessed on 21 Mar 2012 from http://clinicaltrials.gov/show/NCT00176592.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients ClinicalTrials.gov, 18 Dec 2008 Accessed on 21 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00099502.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis ClinicalTrials.gov, 19 Apr 2011 Accessed on 21 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00078338?term=NCT00078338.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript SeekingAlpha.com, 9 May 2012 Accessed on 15 May 2012 from http://seekingalpha.com/article/575201-teva-pharmaceutical-industries-limited-s-ceo-discusses-q1-2012-results-earnings-call-transcript.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response. Gilli F, Navone ND, Valentino P, Granieri L, Perga S, Malucchi S, Bertolotto A Mult Scler. 2012 Oct; 18(10):1484-92. Epub 2012 May 04. PMID: 22562951. Abstract
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis Biogen Idec, 24 Apr 2012 Accessed on 16 May 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1686377.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P Mult Scler. 2012 May 8. PMID: 22570359. Abstract
Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate. Motta E, Gołba A, Huć M, Kazibutowska Z Neurol Neurochir Pol. 2012; 46(2):189-191. PMID: 22581602. Abstract
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS Mult Scler. 2012 May 31. PMID: 22653658. Abstract
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J J Neurol Sci. 2012 Aug 15; 319(1-2):18-23. Epub 2012 Jun 05. PMID: 22676847. Abstract
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. Caragnano M, Tortorella P, Bergami A, Ruggieri M, Livrea P, Specchio L M, Martino G, Trojano M, Furlan R, Avolio C J Neuroimmunol. 2012 Apr; 245(1-2):93-7. Epub 2012 Feb 26. PMID: 22370183. Abstract
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis Market Watch, The Wall Street Journal, 14 Jun 2012 Accessed on 18 Jun 2012 from http://www.marketwatch.com/story/teva-announces-top-line-results-from-gala-phase-iii-trial-evaluating-a-new-dosage-for-glatiramer-acetate-given-three-times-weekly-for-relapsing-remitting-multiple-sclerosis-2012-06-14.
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, Gusev EI, Vandenbroeck K, Favorova OO Pharmacogenomics. 2012 Jan; 13(1):43-53. Epub 2011 Nov 23. PMID: 22111603. Abstract
Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, et al. Eur J Neurol. 2012 Jun 28. PMID: 22741530. Abstract
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A Eur J Clin Pharmacol. 2012 Apr; 68(4):441-8. Epub 2011 Nov 05. PMID: 22057838. Abstract
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx ClinicalTrials.gov, 18 Apr 2012 Accessed on 23 Jul 2012 from http://www.clinicaltrials.gov/ct2/show/NCT00211887.
CombiRx for MS not better than monotherapy Otto AM, Family Practice News, 16 Jul 2012 Accessed on 23 Jul 2012 from http://www.familypracticenews.com/news/more-top-news/single-view/combirx-for-ms-not-better-than-monotherapy/dd2e57672c1b60f9b1c27729a5800e12.html.
Glatiramer acetate induced hepatotoxicity. Subramaniam K, Pavli P, Llewellyn H, Chitturi S Curr Drug Saf. 2012 Apr 1; 7(2):186-8. PMID: 22873505. Abstract
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, Perini P, Gallo P Mult Scler. 2012 Apr; 18(4):418-24. Epub 2011 Jan 12. PMID: 21228025. Abstract
Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Lu E, Wang B W, Guimond C, Synnes A, Sadovnick D, Tremlett H Neurology. 2012 Aug 29. PMID: 22933738. Abstract
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE. Kovalchin J, Krieger J, Genova M, Kawamoto N, Augustyniak M, Collins K, Bloom T, Masci A, Hittinger T, Dufour I, et al. PLoS One. 2011; 6(12):e26274. Epub 2011 Dec 15. PMID: 22194778. Abstract
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate. Mayorga C, Blazquez AB, Doña I, Gomez F, Chaves P, Sanchez-Quintero MJ, Blanca-López N, Melendez L, Blanca M, Torres M J Ann Allergy Asthma Immunol. 2012 Jul; 109(1):47-51. Epub 2012 May 23. PMID: 22727157. Abstract
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. Khan O, Bao F, Shah M, Caon C, Tselis A, Bailey R, Silverman B, Zak I J Neurol Sci. 2012 Jan 15; 312(1-2):7-12. Epub 2011 Sep 13. PMID: 21920559. Abstract
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Hellwig K, Haghikia A, Rockhoff M, Gold R Ther Adv Neurol Disord. 2012 Sep; 5(5):247-53. PMID: 22973421. Abstract
Editors' Pick Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. Fox RJ, Miller DH, Phillips TJ, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al. N Engl J Med. 2012 Sep 20; 367(12):1087-97. Epub 1969 Dec 31. PMID: 22992072. Abstract
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA Curr Med Res Opin. 2012 May; 28(5):767-80. Epub 2012 Apr 24. PMID: 22462530. Abstract
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS Teva Pharmaceutical Industries, 10 Oct 2012 Accessed on 16 Oct 2012 from http://www.tevapharm.com/Media/News/Pages/2012/1743500.aspx.
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, et al. BMC Neurol. 2012; 12:124. Epub 2012 Oct 22. PMID: 23088447. Abstract
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis. Begum-Haque S, Christy M, Wang Y, Kasper E, Ochoa-Reparaz J, Smith JY, Haque A, Kasper LH J Neuroimmunol. 2012 Nov 6. PMID: 23141166. Abstract
FDA denies Teva Copaxone generic trials petition Globes, Israel Business News, 5 Dec 2012 Accessed on 10 Dec 2012 from http://www.globes.co.il/serveen/globes/docview.asp?did=1000804017&fid=1725.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sanchez O, Cano A, Costa-Frossard L, Hernández-Clares R, Sanchez-De la Rosa R, Escala Study Group J Neurol Sci. 2012 Apr 15; 315(1-2):123-8. Epub 2011 Nov 30. PMID: 22133480. Abstract
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung H-P, et al. Mult Scler. 2012 Dec 12. PMID: 23234810. Abstract
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients. Pul R, Morbiducci F, Skuljec J, Skripuletz T, Singh V, Diederichs U, Garde N, Voss E V, Trebst C, Stangel M PLoS One. 2012; 7(12):e51867. Epub 2012 Dec 20. PMID: 23284793. Abstract
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Gavasso S, Torkildsen Ø, Marøy TH, Ulvestad E, Myhr K-M, Vedeler CA Acta Neurol Scand Suppl. 2012(195):84-9. PMID: 23278662. Abstract
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury. Smirnov I, Walsh JT, Kipnis J Brain Behav Immun. 2013 Jan 4. PMID: 23295266. Abstract
Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis. Gentile A, Rossi S, Studer V, Motta C, De Chiara V, Musella A, Sepman H, Fresegna D, Musumeci G, Grasselli G, et al. J Neuroimmune Pharmacol. 2013 Jan 31. Epub 2013 Jan 31. PMID: 23370991. Abstract
Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis. J Med Econ. 2013 Feb 7. PMID: 23391123. Abstract
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J, FOCUS study group Health Qual Life Outcomes. 2010; 8:133. Epub 2010 Nov 15. PMID: 21078142. Abstract
BRIEF: Teva files for Copaxone-Laquinimod patent Middle East North Africa Financial Network, 13 Feb 2013 Accessed on 18 Feb 2013 from http://www.menafn.com/menafn/46d9c3c8-74ec-4f41-a64f-6aa0560bdea7/BRIEF-Teva-files-for-CopaxoneLaquinimod-patent?src=main.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Romeo M, Martinelli-Boneschi F, Rodegher M, Esposito F, Martinelli V, Comi G, San Raffaele Multiple Sclerosis Clinical Group Eur J Neurol. 2013 Feb 20. PMID: 23425504. Abstract
Editors' Pick Randomized study combining interferon & glatiramer acetate in multiple sclerosis. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, for the CombiRx Investigators. Ann Neurol. 2013 Feb 19. Epub 1969 Dec 31. PMID: 23424159. Abstract
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice. Poittevin M, Deroide N, Azibani F, Delcayre C, Giannesini C, Levy BI, Pocard M, Kubis N J Neuroimmunol. 2013 Jan 15; 254(1-2):55-62. Epub 2012 Sep 29. PMID: 23026222. Abstract
Gene expression analysis reveals functional pathways of glatiramer acetate activation. Bakshi S, Chalifa-Caspi V, Plaschkes I, Perevozkin I, Gurevich M, Schwartz R Expert Opin Ther Targets. 2013 Apr; 17(4):351-362. Epub 2013 Mar 08. PMID: 23469939. Abstract
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status Biogen Idec, 18 Mar 2013 Accessed on 21 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1797077.
Extension CombiRx data show no benefit of combined MS drugs Medscape Medical News, 21 Mar 2013 Accessed on 25 Mar 2013 from http://www.medscape.com/viewarticle/781153.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. Duchi S, Ovadia H, Touitou E J Neuroimmunol. 2013 Mar 18. PMID: 23517929. Abstract
Editors' Pick The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, Liew D, Butzkueven H, Slee M, Slee M PLoS One. 2013; 8(3):e59694. Epub 2013 Mar 19. PMID: 23527252. Abstract
Synthetic Biologics announces issuance of U.S. patent covering combination of estriol and Copaxone® for multiple sclerosis Synthetic Biologics, 4 Apr 2013 Accessed on 8 Apr 2013 from http://www.syntheticbiologics.com/2013-04-04-Synthetic-Biologics-Announces-Issuance-of-U-S-Patent-Covering-Combination-of-Estriol-and-Copaxone-for-Multiple-Sclerosis.
Decreased microglial activation in MS patients treated with glatiramer acetate. Ratchford JN, Endres CJ, Hammoud DA, Pomper MG, Shiee N, McGready J, Pham DL, Calabresi PA J Neurol. 2012 Jun; 259(6):1199-205. Epub 2011 Dec 09. PMID: 22160466. Abstract
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells. Yao Y, Han W, Liang J, Ji J, Wang J, Cantor H, Lu L Eur J Immunol. 2013 Jan; 43(1):125-36. Epub 2012 Nov 07. PMID: 23002042. Abstract
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, Karandikar NJ Clin Immunol. 2013 May; 147(2):105-19. Epub 2013 Mar 06. PMID: 23578552. Abstract
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. Arnold DL, Narayanan S, Antel S J Neurol. 2013 Apr 16. PMID: 23589190. Abstract
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication. Festoff BW, Li C, Woodhams B, Lynch S J Neurol Sci. 2012 Dec 15; 323(1-2):61-5. Epub 2012 Sep 08. PMID: 22967748. Abstract
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model. Rosato Siri MV, Badaracco ME, Pasquini JM Neurochem Int. 2013 Apr 22. PMID: 23619394. Abstract
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA). Høglund RA, Holmøy T, Harbo HF, Maghazachi AA PLoS One. 2013; 8(4):e62237. Epub 2013 Apr 22. PMID: 23614042. Abstract
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. Sellner J, Koczi W, Harrer A, Oppermann K, Obregon-Castrillo E, Pilz G, Wipfler P, Afazel S, Haschke-Becher E, Trinka E, et al. Clin Exp Immunol. 2013 Apr 24. PMID: 23611040. Abstract
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone Cohen T, Reuters, 2 May 2013 Accessed on 5 May 2013 from http://www.reuters.com/article/2013/05/02/tevapharm-results-idUSL6N0DJ35O20130502.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis Mapi Pharma, 6 May 2013 Accessed on 21 May 2013 from http://www.mapi-pharma.com/news/?pid=30.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. Oreja-Guevara C, Ramos-Cejudo J, Stark Aroeira L, Chamorro B, Diez-Tejedor E BMC Neurol. 2012; 12:95. Epub 2012 Sep 18. PMID: 22989378. Abstract
Editors' Pick Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, for the GALA Study Group Ann Neurol. 2013 May 20. PMID: 23686821. Abstract
Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies. Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Borter E, Traber M Eur Neurol. 2013 May 14; 70(1):35-41. Epub 2013 May 14. PMID: 23689307. Abstract
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week Business Wire, 30 May 2013 Accessed on 31 May 2013 from http://www.businesswire.com/news/home/20130530005718/en/Teva-Announces-FDA-Acceptance-sNDA-Higher-Concentration.
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G, Giovane C D, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G Cochrane Database Syst Rev. 2013 Jun 6; 6:CD008933. PMID: 23744561. Abstract
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Campbell JD, McQueen BR, Miravalle A, Corboy JR, Ackermann RT, Vollmer TL, Nair K Am J Manag Care. 2013; 19(4):278-85. PMID: 23725360. Abstract
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Hutchinson M, Fox RJ, Miller DH, Phillips TJ, Kita M, Havrdova E, O'Gorman J, Zhang R, Novas M, Viglietta V, et al. J Neurol. 2013 Jun 8. PMID: 23749293. Abstract
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators. Peelen E, Thewissen M, Knippenberg S, Smolders J, Muris A-H, Menheere P, Tervaert CJW, Hupperts R, Damoiseaux J J Neuroimmunol. 2013 May 15; 258(1-2):77-84. Epub 2013 Mar 19. PMID: 23517930. Abstract
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors. Song F, Bandara M, Deol H, Loeb JA, Benjamins J, Lisak RP J Neuroimmunol. 2013 Jun 10. PMID: 23763772. Abstract
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. Carotenuto A, Iodice R, Barbato F, Orefice N S, Orefice G J Neurol Sci. 2013 Jun 15. PMID: 23778027. Abstract
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease. Tyler AF, Mendoza JP, Firan M, Karandikar NJ PLoS One. 2013; 8(6):e66772. Epub 2013 Jun 21. PMID: 23805274. Abstract
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis]. Kravtsov II, Kicherova OA Zh Nevrol Psikhiatr Im S S Korsakova. 2013; 113(3):69-71. PMID: 23612414. Abstract
US court permits generic version of Teva MS drug a year sooner Bartz D, Pierson R, Reuters, 26 Jul 2013 Accessed on 29 Jul 2013 from http://www.reuters.com/article/2013/07/26/teva-copaxone-patent-idUSL1N0FW17H20130726.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Makhani N, Ngan B-Y, Kamath BM, Yeh AE Neurology. 2013 Jul 24. PMID: 23884038. Abstract
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015 Market Watch, The Wall Street Journal, 29 Jul 2013 Accessed on 8 Aug 2013 from http://www.marketwatch.com/story/english-court-of-appeal-finds-in-favor-of-teva-on-copaxoner-patent-litigation-and-upholds-validity-of-copaxone-patent-until-may-2015-2013-07-29?reflink=MW_news_stmp.
Editors' Pick An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL Sci Transl Med. 2012 Sep 26; 4(153):153ra131. PMID: 23019656. Abstract
Patient trial of immunization to treat Alzheimer’s disease begins at Cedars-Sinai Cedars-Sinai, 13 Aug 2013 Accessed on 18 Aug 2013 from http://www.cedars-sinai.edu/About-Us/News/News-Releases-2013/Patient-trial-of-immunization-to-treat-Alzheimer’s-disease-begins-at-Cedars-Sinai.aspx.
Editors' Pick A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E J Clin Pharm Ther. 2013 Aug 20. PMID: 23957759. Abstract
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, et al. Mult Scler. 2013 Sep 4. PMID: 24005026. Abstract
Editors' Pick Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla A, Karkare SU, Balderston McGuiness C, Korn JR Curr Med Res Opin. 2013 Oct 1. Epub 1969 Dec 31. PMID: 24059944. Abstract
Oxidative modification of serum proteins in multiple sclerosis. Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G Neurochem Int. 2013 Sep 12. PMID: 24036284. Abstract
Teva to present further results of twenty-year open-label extension study of glatiramer acetate 20 mg daily for relapsing-remitting multiple sclerosis Teva Pharmaceutical Industries, 3 Oct 2013 Accessed on 4 Oct 2013 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1861304.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW BMC Neurol. 2013 Oct 4; 13(1):138. Epub 2013 Oct 04. PMID: 24093542. Abstract
Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review. Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND, Barreira AA, Brooks JBB, Carneiro DSD, Carvalho MJ, Claudino R, Comini-Frota ER, et al. CNS Drugs. 2013 Oct 10. PMID: 24114585. Abstract
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients. Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D Cardiovasc Ther. 2013 Oct 1. PMID: 24119301. Abstract
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. Thamilarasan M, Hecker M, Goertsches R H, Paap B K, Schröder I, Koczan D, Thiesen H-J, Zettl U K J Neuroinflammation. 2013 Oct 17; 10(1):126. Epub 2013 Oct 17. PMID: 24134771. Abstract
Assessment of structural and functıonal vısual outcomes ın relapsıng remıttıng multıple sclerosıs wıth vısual evoked potentıals and optıcal coherence tomography. Tugcu B, Soysal A, Kılıc M, Yuksel B, Kale N, Yıgıt U, Arpaci B J Neurol Sci. 2013 Oct 1. PMID: 24148562. Abstract
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM, Johnson BH, Wenten M, Watson C Clin Ther. 2013 Oct; 35(10):1501-12. PMID: 24139422. Abstract
Editors' Pick Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz B Curr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract
Glatiramer acetate ameliorates experimental autoimmune neuritis. Zhang C-J, Zhai H, Yan Y, Hao J, Li M-S, Jin W-N, Su N, Vollmer TL, Shi F-D Immunol Cell Biol. 2013 Nov 26. PMID: 24275856. Abstract
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan The Wall Street Journal, 4 Dec 2013 Accessed on 4 Dec 2013 from http://online.wsj.com/article/PR-CO-20131204-902576.html?dsk=y.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis. Piras G, Rattazzi L, McDermott A, Deacon R, D'Acquisto F Front Immunol. 2013; 4:400. Epub 2013 Nov 21. PMID: 24312102. Abstract
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath. You Y, Zhao Y, Bai H, Liu Z, Meng F, Zhang H, Xu R Eur J Pharm Sci. 2013 Jun 14; 49(3):366-70. Epub 2013 Apr 21. PMID: 23611724. Abstract
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr K-M Mult Scler. 2014 Jan 16. PMID: 24436455. Abstract 1 member recommends
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010. Oleen-Burkey M, Cyhaniuk A, Swallow E BMC Neurol. 2014; 14(1):11. Epub 2014 Jan 14. PMID: 24423119. Abstract
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. Fox RJ, Salter AR, Tyry T, Sun J, You X, Laforet G, Campagnolo D Int J MS Care. 2013 Winter; 15(4):194-201. PMID: 24453783. Abstract
Relationship between disease-modifying therapy and depression in multiple sclerosis. Kirzinger SS, Jones J, Siegwald A, Crush A B Int J MS Care. 2013 Fall; 15(3):107-12. PMID: 24453772. Abstract
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® (glatiramer acetate injection) 40mg/mL Market Watch, The Wall Street Journal, 28 Jan 2014 Accessed on 30 Jan 2014 from http://www.marketwatch.com/story/teva-announces-us-fda-approval-of-three-times-a-week-copaxone-glatiramer-acetate-injection-40mgml-2014-01-28?reflink=MW_news_stmp.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic. Towfic F, Funt JM, Fowler KD, Bakshi S, Blaugrund E, Artyomov MN, Hayden MR, Ladkani D, Schwartz R, Zeskind B PLoS One. 2014; 9(1):e83757. Epub 2014 Jan 08. PMID: 24421904. Abstract
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate. From R, Eilam R, Bar-Lev DD, Levin-Zaidman S, Tsoory M, Lopresti P, Sela M, Arnon R, Aharoni R Glia. 2014 Apr; 62(4):649-65. Epub 2014 Jan 30. PMID: 24481644. Abstract
Editors' Pick Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla AA, Karkare SU, Balderston McGuiness C, Korn JR PLoS One. 2014; 9(2):e88472. Epub 2014 Feb 06. PMID: 24516663. Abstract
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, et al. Mult Scler. 2014 Feb 10. PMID: 24515732. Abstract
Glatiramer acetate does not protect from acute ischemic stroke in mice. Kraft P, Göbel K, Meuth SG, Kleinschnitz C Exp Transl Stroke Med. 2014; 6(1):4. Epub 2014 Feb 27. PMID: 24576335. Abstract
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Río J, Rovira A, Tintoré M, Sastre-Garriga J, Castilló J, Auger C, Nos C, Comabella M, Tur C, Vidal A, et al. Mult Scler. 2014 Mar 12. PMID: 24622350. Abstract
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs. Lu E, Zhu F, Zhao Y, van der Kop M, Synnes A, Dahlgren L, Sadovnick DA, Traboulsee A, Tremlett H CNS Drugs. 2014 Mar 19. PMID: 24643915. Abstract
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate Synthon, 27 Mar 2014 Accessed on 1 Apr 2014 from http://www.synthon.com/Corporate/News/PressReleases/Synthon-announces-successful-outcome-of-the-PhaseIII-GATE-study-with-its-generic-glatiramer-acetate?sc_lang=en.
Efficacy and Safety of GTR in Comparison to Copaxone® (GATE) ClinicalTrials.gov, 31 Mar 2014 Accessed on 1 Apr 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01489254.
Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1. Lu H, Zeng C, Zhao H, Lian L, Dai Y Biochem Biophys Res Commun. 2014 Mar 18. PMID: 24657155. Abstract
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent The Wall Street Journal, 31 Mar 2014 Accessed on 2 Apr 2014 from http://online.wsj.com/article/PR-CO-20140331-910272.html.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics. Evangelidou M, Karamita M, Vamvakas S-S, Szymkowski DE, Probert L J Immunol. 2014 Mar 28. PMID: 24683189. Abstract
Editors' Pick MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Fox RJ, Cree BAC, De Sèze J, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, et al. Neurology. 2014 Apr 9. Epub 2014 Mar 28. PMID: 24682966. Abstract
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008. Tsai C-P, Lee C T-C Clin Drug Investig. 2013 Jul 17. PMID: 23861171. Abstract
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight The Jerusalem Post, 18 Apr 2014 Accessed on 5 May 2014 from http://www.jpost.com/Business/Business-News/US-top-court-denies-Israels-Teva-Pharmaceuticals-stay-in-Copaxone-patent-fight-349886.
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. Menzin J, Caon C, Nichols C, White L A, Friedman M, Pill MW J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S24-40. PMID: 23383731. Abstract
Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial Adeona Pharmaceuticals, 9 Sep 2011 Accessed on 3 Jan 2012 from http://www.syntheticbiologics.com/index.php?s=43&item=90.
A Combination Trial of Copaxone plus Estriol in Relapsing Remitting Multiple Sclerosis ClinicalTrials.gov, 23 Jan 2012 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00451204.
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS Synthetic Biologics, 29 Apr 2014 Accessed on 5 May 2014 from http://www.syntheticbiologics.com/2014-04-29-Synthetic-Biologics-Reports-UCLA-Announcement-of-Preliminary-Positive-Topline-Efficacy-and-Safety-Results-from-Investigator-Led-Phase-II-Study-of-Trimesta-for-Relapsing-Remitting-Multiple-Sclerosis.
Safety and Tolerability of Glatiramer Acetate (GLACIER) ClinicalTrials.gov, 14 Apr 2014 Accessed on 15 May 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01874145.
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Kulakova OG, Tsareva E Y, Lvovs D, Favorov AV, Boyko AN, Favorova OO Pharmacogenomics. 2014 Apr; 15(5):679-85. PMID: 24798724. Abstract
Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. Jongen P J, Lehnick D, Koeman J, Frequin S, Heersema D, Kornips B, Schyns-Soeterboek A, Visser LH, Schiphof P, Valkenburg A, et al. J Neurol. 2014 May 3. Epub 2014 May 03. PMID: 24792727. Abstract
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S J Neuroimmunol. 2014 Apr 24. PMID: 24814390. Abstract
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis Market Watch, The Wall Street Journal, 27 May 2014 Accessed on 29 May 2014 from http://www.marketwatch.com/story/mapi-pharma-receives-additional-claims-for-its-us-patent-for-glatiramer-acetate-depot-for-the-treatment-of-multiple-sclerosis-2014-05-27.
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, et al. BMC Neurol. 2014 May 26; 14(1):114. Epub 2014 May 26. PMID: 24884599. Abstract
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T PLoS One. 2011; 6(9):e24604. Epub 2011 Sep 16. PMID: 21949733. Abstract
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis. Văcăraş V, Major ZZ, Mureşanu DF, Krausz TL, Mărginean I, Buzoianu DA CNS Neurol Disord Drug Targets. 2014 Jun 18. PMID: 24938775. Abstract
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Edgar CM, Brunet DG, Fenton P, McBride VE, Green P Can J Neurol Sci. 2004 Feb; 31(1):58-63. PMID: 15038472. Abstract
[Nicolau syndrome after administration of glatiramer acetate]. Pulido Pérez A, Parra Blanco V, Suárez Fernández R Neurologia. 2013 Sep; 28(7):448-9. Epub 2012 Jun 13. PMID: 22698594. Abstract
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(5):65-9. PMID: 24988963. Abstract
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate. Moore S, Khalaj AJ, Patel R, Yoon J, Ichwan D, Hayardeny L, Tiwari-Woodruff SK J Neurosci Res. 2014 Jul 3. PMID: 24989965. Abstract
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, Balderston McGuiness C, Korn JR J Med Econ. 2014 Jul 23:1-12. PMID: 25019581. Abstract
Treatment satisfaction in multiple sclerosis. Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC Int J MS Care. 2014 Summer; 16(2):68-75. PMID: 25061430. Abstract
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate. Márquez-Rebollo C, Vergara-Carrasco L, Díaz-Navarro R, Rubio-Fernández D, Francoli-Martínez P, Sánchez-de la Rosa R Adv Ther. 2014 Jul 22. Epub 2014 Jul 22. PMID: 25047757. Abstract
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A Cochrane Database Syst Rev. 2014; 7:CD009333. Epub 1969 Dec 31. PMID: 25062935. Abstract
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. Ortega-Madueño I, Garcia-Montojo M, Dominguez-Mozo M I, Garcia-Martinez A, Arias-Leal A M, Casanova I, Arroyo R, Alvarez-Lafuente R PLoS One. 2014; 9(8):e104836. Epub 2014 Aug 11. PMID: 25110949. Abstract
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis. Michaud CJ, Bockheim HM, Nabeel M, Daum TE Case Rep Neurol Med. 2014; 2014:786342. Epub 2014 Jul 03. PMID: 25105037. Abstract
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. Ziemssen T, Bajenaru OA, Carrá A, De Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, et al. J Neurol. 2014 Aug 14. Epub 2014 Aug 14. PMID: 25119836. Abstract
Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA Mylan, 28 Aug 2014 Accessed on 2 Sep 2014 from http://www.mylan.com/news/press-releases/item?id=123246.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg Teva, 11 Sep 2014 Accessed on 15 Sep 2014 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1966166.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance. Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O J Neuroimmunol. 2014 Sep 2. PMID: 25227585. Abstract
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson C BMJ Open. 2014; 4(1):e004073. PMID: 24441054. Abstract
Beta-Interferon, Glatiramer Acetate Cost-Effective in MS Hughes S, Medscape Medical News, 18 Sep 2014 Accessed on 23 Sep 2014 from http://www.medscape.com/viewarticle/831921.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. Balak D M, Hengstman G J, Hajdarbegovic E, van den Brule R J, Hupperts RMM, Thio H B BMC Neurol. 2013 Oct 16; 13(1):146. Epub 2013 Oct 16. PMID: 24131589. Abstract
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis. Ireland SJ, Guzman AA, O'Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, et al. JAMA Neurol. 2014 Sep 29. PMID: 25264704. Abstract
Editors' Pick Long-term effectiveness of glatiramer acetate in clinical practice conditions. Arnal-García C, Amigo-Jorrin M D C, López-Real A M, Lema-Devesa C, Llopis N, Sánchez-de la Rosa R, XPERIENCIA-5 Study Group J Clin Neurosci. 2014 Sep 22. Epub 1969 Dec 31. PMID: 25257663. Abstract
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome. Kuzina E, Kudriaeva A, Smirnov I, Dubina MV, Gabibov A, Belogurov A Biomed Res Int. 2014; 2014:926394. Epub 2014 Sep 08. PMID: 25276831. Abstract
The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS Baranzini SE, Katz-Sand I, Mazmanian SK, Becosme Y, London J, Farber R, Kanner R, Gomez R, Cree BA, Knight R, et al. Accessed on 14 Oct 2014 from http://www.professionalabstracts.com/msboston2014/planner/index.php?go=abstract&action=abstract_show&absno=754&. Abstract P618, Joint ACTRIMS-ECTRIMS meeting, Boston 2014
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. Corey-Bloom J, Jia H, Aikin AM, Thomas EA J Huntingtons Dis. 2014; 3(3):311-6. PMID: 25300334. Abstract
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Darbà J, Kaskens L, Sánchez-de la Rosa R J Med Econ. 2014 Mar; 17(3):215-22. PMID: 24494728. Abstract
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. Thomas K, Dietze K, Wehner R, Metz I, Tumani H, Schultheiß T, Günther C, Schäkel K, Reichmann H, Brück W, et al. Neurol Neuroimmunol Neuroinflamm. 2014 Oct; 1(3):e33. Epub 2014 Sep 18. PMID: 25340085. Abstract
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. Zagmutt FJ, Carroll CA Int J Neurosci. 2014 Nov 24. PMID: 25387069. Abstract
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. Sternberg Z, Sternberg D, Drake A, Chichelli T, Yu J, Hojnacki D J Neuroimmunol. 2014 Sep 15; 274(1-2):197-201. Epub 2014 Jul 15. PMID: 25064498. Abstract
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Beaber B E, Chi MD, Brara S M, Zhang J L, Langer-Gould AM Perm J. 2014 Winter; 18(1):9-13. PMID: 24626066. Abstract
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS) Teva Pharmaceutical Industries Ltd., 4 Dec 2014 Accessed on 9 Dec 2014 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1995004.
Glatiramer Acetate Guards Against Rapid Memory Decline During Relapsing-Remitting Experimental Autoimmune Encephalomyelitis. Lopresti P Neurochem Res. 2014 Dec 7. Epub 2014 Dec 07. PMID: 25481047. Abstract
Editors' Pick Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, et al. Mult Scler. 2014 Dec 5. PMID: 25480857. Abstract
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, et al. J Immunol Res. 2014; 2014:961863. Epub 2014 Mar 26. PMID: 24741637. Abstract
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS) Mapi Pharma, 17 Dec 2014 Accessed on 23 Dec 2014 from http://www.mapi-pharma.com/first-patient-treated-in-mapi-pharmas-phase-iia-clinical-trial-of-ga-depot-for-relapsing-remitting-multiple-sclerosis-rrms/.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS ClinicalTrials.gov, 12 Dec 2014 Accessed on 23 Dec 2014 from https://clinicaltrials.gov/ct2/show/NCT02212886.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway. Wei G, Zhang X, Su Z, Li X Biochem Biophys Res Commun. 2014 Dec 19. PMID: 25529444. Abstract
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A J Neurol Neurosurg Psychiatry. 2014 Dec 30. PMID: 25550414. Abstract
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V, Khan O J Neurol. 2014 Dec 27. Epub 2014 Dec 27. PMID: 25542295. Abstract
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis Takeda, 25 Dec 2015 Accessed on 6 Jan 2015 from https://www.takeda.com/news/2014/20141225_6846.html.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review Teva Pharmaceutical Industries, 20 Jan 2015 Accessed on 27 Jan 2015 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2008891.
Enhanced myelination in autoimmunity and in normal development induced by glatiramer acetate. Aharoni R, Arnon R Isr Med Assoc J. 2014 Oct; 16(10):611-3. PMID: 25438444. Abstract
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis. Corominas M, Postigo I, Cardona V, Lleonart R, Romero-Pinel L, Martinez J Int Arch Allergy Immunol. 2014; 165(4):244-6. Epub 2015 Jan 29. PMID: 25634237. Abstract
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, et al. JAMA Neurol. 2015 Feb 9:1-10. PMID: 25665031. Abstract
Meralgia paresthetica after subcutaneous injection of glatiramer acetate. Lagueny A, Ouallet J C Muscle Nerve. 2015 Feb 20. PMID: 25703091. Abstract
Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, Venkatesan A, Fraser CM, Mowry EM J Investig Med. 2015 Mar 14. PMID: 25775034. Abstract
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study. Rinaldi F, Perini P, Atzori M, Favaretto A, Seppi D, Gallo P Mult Scler Int. 2015; 2015:369348. Epub 2015 Feb 23. PMID: 25802758. Abstract
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse. Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H Mult Scler Relat Disord. 2015 Jan; 4(1):75-82. Epub 2014 Oct 07. PMID: 25787057. Abstract
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats. Cruz Y, Lorea J, Mestre H, Kim-Lee J H, Herrera J, Mellado R, Gálvez V, Cuellar L, Musri C, Ibarra A PLoS One. 2015; 10(3):e0121854. Epub 2015 Mar 30. PMID: 25821957. Abstract
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids. Rossi S, Motta C, Studer V, Boffa L, De Chiara V, Castelli M, Barbieri F, Buttari F, Monteleone F, Germani G, et al. CNS Neurosci Ther. 2014 May 19. PMID: 24837039. Abstract
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, et al. Lancet Neurol. 2015 Apr 1. PMID: 25841667. Abstract
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. Zhornitsky S, Greenfield J, Koch MW, Patten SB, Harris C, Wall W, Alikhani K, Burton J, Busche K, Costello F, et al. PLoS One. 2015; 10(4):e0123824. Epub 2015 Apr 13. PMID: 25867095. Abstract
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg Momenta, 16 Apr 2015 Accessed on 21 Apr 2015 from http://files.shareholder.com/downloads/MNTA/70100481x0x821673/F5FCB506-E766-4DEC-876E-BD7A8982D9F5/MNTA_News_2015_4_16_General_Releases.pdf.
Does glatiramer acetate provoke hepatitis in multiple sclerosis? Sinagra E, Raimondo D, Cottone S, Guddo F, Gabriele Rizzo A, Amvrosiadis G, Perricone G, Cottone M, Madonia S Mult Scler Relat Disord. 2014 Mar; 3(2):266-8. Epub 2013 Oct 08. PMID: 25878015. Abstract
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis. La Gioia S, Bacis G, Sonzogni A, Frigeni B, Conti M Z, Vedovello M, Rottoli M R Mult Scler Relat Disord. 2014 Nov; 3(6):732-4. Epub 2014 Aug 15. PMID: 25891553. Abstract
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C. Business Wire, 23 Apr 2015 Accessed on 28 Apr 2015 from http://www.businesswire.com/news/home/20150423005324/en/Teva-Presents-Data-Comparing-Early-Treatment-COPAXONE®#.VT-C_ijOZiY.
Comparative efficacy of switching to natalizumab in active multiple sclerosis. Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, et al. Ann Clin Transl Neurol. 2015 Apr; 2(4):373-87. Epub 2015 Feb 27. PMID: 25909083. Abstract
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate Synthon, 28 Apr 2015 Accessed on 12 May 2015 from http://www.synthon.com/Corporate/News/PressReleases/Synthon-Announces-Successful-Outcomes-from-the-Open-label-extension-of-the-GATE-Study?sc_lang=en.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate. Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, et al. Metabolism. 2015 May 8. PMID: 25986733. Abstract
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, et al. Sci Rep. 2015; 5:10191. PMID: 25998228. Abstract
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit Momenta, 18 Jun 2015 Accessed on 23 Jun 2015 from http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=918548.
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg Momenta, 18 Jun 2015 Accessed on 23 Jun 2015 from http://ir.momentapharma.com/releasedetail.cfm?releaseid=918623.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Izquierdo G, García-Agua Soler N, Rus M, García-Ruiz A J Brain Behav. 2015 Jun; 5(6):e00337. Epub 2015 May 01. PMID: 26085963. Abstract
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation. Starossom SC, Veremeyko T, Dukhinova M, Yung AWY, Ponomarev ED PLoS One. 2014; 9(5):e96256. Epub 2014 May 02. PMID: 24788965. Abstract
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH, Bonafede MM, Watson C CNS Drugs. 2015 Jun 26. PMID: 26113055. Abstract
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis. Wolinsky JS, Borresen ET, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, Knappertz V, Kolodny S, GLACIER Study Group Mult Scler Relat Disord. 2015 Jul; 4(4):370-6. PMID: 26195058. Abstract
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D, Schmitz N, Kugler J PLoS One. 2015; 10(7):e0133279. Epub 2015 Jul 27. PMID: 26214805. Abstract
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study. Lus G, Signoriello E, Maniscalco GT, Bonavita S, Signoriello S, Gallo C Eur J Neurol. 2015 Jul 26. PMID: 26212486. Abstract
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis Synthon, 3 Aug 2015 Accessed on 5 Aug 2015 from http://www.synthon.com/Corporate/News/PressReleases/Pfizer-and-Synthon-Enter-Into-US-Commercialization-Agreement-for-Potential-Generic-Treatment-of-MS.aspx.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon. Fernández-Fournier M, Tallón-Barranco A, Chamorro B, Martínez-Sánchez P, Puertas I BMC Neurol. 2015; 15:141. Epub 2015 Aug 19. PMID: 26286576. Abstract
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response. Singh J, Deshpande M, Suhail H, Rattan R, Giri S J Neuroimmune Pharmacol. 2015 Aug 16. Epub 2015 Aug 16. PMID: 26277791. Abstract
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore G B, Marrosu M G, et al. Brain. 2015 Sep 11. PMID: 26362907. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients. Rovituso DM, Duffy CE, Schroeter M, Kaiser CC, Kleinschnitz C, Bayas A, Elsner R, Kuerten S Sci Rep. 2015; 5:14265. PMID: 26387426. Abstract
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR, Khan O J Neuroimaging. 2015 Sep 22. PMID: 26394270. Abstract
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis Business Wire, 28 Sep 2015 Accessed on 29 Sep 2015 from http://www.businesswire.com/news/home/20150928005506/en/Takeda-Pharmaceutical-Drug-Application-Approval-Japan-Copaxone®#.Vgr0Ps4buXs.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, Nguyen V, Royal W, Bever CT, Rus V, et al. Exp Mol Pathol. 2015 Sep 25; 99(3):498-505. PMID: 26407760. Abstract
Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Ehling R, Di Pauli F, Lackner P, Rainer C, Kraus V, Hegen H, Lutterotti A, Kuenz B, De Zordo T, Schocke M, et al. J Neuroimmunol. 2015 Oct 15; 287:98-105. Epub 2015 Aug 10. PMID: 26439969. Abstract
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients Biogen, 7 Oct 2015 Accessed on 13 Oct 2015 from http://media.biogen.com/press-release/neurology/new-data-show-strong-sustained-effects-tecfidera-dimethyl-fumarate-newly-dia.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis Teva, 8 Oct 2015 Accessed on 13 Oct 2015 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2095367.
Editors' Pick Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Cohen J, Belova A, Selmaj K, Wolf C, Sormani M P, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, et al. JAMA Neurol. 2015 Oct 12:1-9. Epub 1969 Dec 31. PMID: 26458034. Abstract
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®. D'Alessandro JS, Duffner J, Pradines J, Capila I, Garofalo K, Kaundinya G, Greenberg BM, Kantor D, Ganguly TC PLoS One. 2015; 10(10):e0140299. Epub 2015 Oct 16. PMID: 26473741. Abstract
Editors' Pick Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Sánchez-de la Rosa R, García-Bujalance L, Meca-Lallana J Health Econ Rev. 2015 Dec; 5(1):30. Epub 2015 Oct 16. PMID: 26475277. Abstract
Effect of vitamin D on MS activity by disease-modifying therapy class. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167. Epub 2015 Oct 29. PMID: 26568968. Abstract
Glatiramer acetate treatment negatively regulates type I interferon signaling. Molnarfi N, Prod'homme T, Schulze-Topphoff U, Spencer CM, Weber MS, Patarroyo JC, Lalive PH, Zamvil SS Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e179. Epub 2015 Nov 09. PMID: 26601118. Abstract
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand KV PLoS One. 2015; 10(11):e0143393. Epub 2015 Nov 23. PMID: 26600308. Abstract
Editors' Pick Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Voskuhl RR, Wang HJ, Wu JTC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, et al. Lancet Neurol. 2015 Nov 24. PMID: 26621682. Abstract
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report. Zecca C, Mainetti C, Blum R, Gobbi C BMC Neurol. 2015; 15:249. Epub 2015 Dec 02. PMID: 26630967. Abstract
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Kaufman M, Cree BAC, De Sèze J, Fox RJ, Gold R, Hartung H-P, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, et al. J Neurol. 2015 Feb; 262(2):326-36. Epub 2014 Nov 09. PMID: 25381458. Abstract
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, et al. J Clin Invest. 2002 Mar; 109(5):641-9. PMID: 11877472. Abstract
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ J Immunol. 2006 Jun 1; 176(11):7119-29. PMID: 16709875. Abstract
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, Shacham-Abramson M, Timan B, Fowler KD, Birnberg T, et al. J Neuroimmunol. 2016 Jan 15; 290:84-95. Epub 2015 Nov 24. PMID: 26711576. Abstract
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T J Med Econ. 2015 Dec 26:1-36. PMID: 26707273. Abstract
Glatiramer acetate during early pregnancy: A prospective cohort study. Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K Mult Scler. 2016 Jan 11. PMID: 26754804. Abstract
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'maison F, et al. Eur J Neurol. 2016 Jan 19. PMID: 26782663. Abstract
Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O, Kümpfel T, Krumbholz M, Trebst C, Paul F, et al. J Neurol. 2016 Jan 25. PMID: 26810718. Abstract
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis Synthetic Biologics, 2 Feb 2016 Accessed on 9 Feb 2016 from http://www.syntheticbiologics.com/news-media/press-releases/detail/198/synthetic-biologics-reports-results-of-independent-third.
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. Ziemssen T, Calabrese P, Penner I-K, Apfel R J Neurol. 2016 Feb 25. Epub 2016 Feb 25. PMID: 26914926. Abstract
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L, Guo S, Kinter E, Fay M J Med Econ. 2016 Mar 7:1-12. PMID: 26947984. Abstract
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJA, Strijbis EMM, Steenwijk MD, Polman CH, Pouwels PJW, Barkhof F, Geurts JJG AJNR Am J Neuroradiol. 2016 Mar 10. PMID: 26965463. Abstract
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J, Chamoux C, Hammès F, Chicoye A PLoS One. 2016; 11(3):e0150703. Epub 2016 Mar 17. PMID: 26987055. Abstract
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. Signori A, Gallo F, Bovis F, Di Tullio N, Maietta I, Sormani M P Mult Scler Relat Disord. 2016 Mar; 6:57-63. Epub 2016 Feb 02. PMID: 27063624. Abstract
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe Synthon, 12 Apr 2016 Accessed on 19 Apr 2016 from http://www.synthon.com/Corporate/News/PressReleases/Synthon-obtains-approval-for-glatiramer-acetate-20-mg-mL-in-Europe.aspx.